Lakefront Biotherapeutics - American Depositary Shares (LKFT) closed at $34.39 on November 17, 2026, down 1.1% from the previous close, on volume of 226,699 shares (30-day average 267,101).
Data as of November 17, 2026.
Lakefront Biotherapeutics initiates new €50M share repurchase program
Seeking Alpha News (Mon, 16-Nov 2:39 AM ET)
Globe Newswire (Mon, 16-Nov 1:30 AM ET)
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Fri, 13-Nov 5:50 AM ET)
Lakefront Biotherapeutics Reports Nine Months 2026 Financial Results and Provides Business Update
Globe Newswire (Wed, 11-Nov 4:01 PM ET)
Lakefront to Present at the 2026 Jefferies Global Healthcare Conference in London
Globe Newswire (Tue, 10-Nov 4:01 PM ET)
Globe Newswire (Wed, 4-Nov 9:01 AM ET)
Lakefront Biotherapeutics Welcomes Dr. Mehdi Shahidi to its Board of Directors
Globe Newswire (Mon, 2-Nov 4:01 PM ET)
Lakefront Announces Sale of Preclinical CAR-T Programs to Armed Cell Therapeutics
Globe Newswire (Wed, 14-Oct 4:01 PM ET)
Lakefront Receives Transparency Notification from Bank of America
Globe Newswire (Thu, 8-Oct 4:01 PM ET)
Globe Newswire (Tue, 22-Sep 4:01 PM ET)
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.
Lakefront Biotherapeutics - American Depositary Shares trades on the NASDAQ stock market under the symbol LKFT.
As of November 18, 2026, LKFT stock price declined to $34.26 with 93,258 million shares trading.
LKFT has a beta of -0.07, meaning it tends to be less sensitive to market movements. LKFT has a correlation of 0.00 to the broad based SPY ETF.
LKFT has a market cap of $2.26 billion. This is considered a Mid Cap stock.
Last quarter Lakefront Biotherapeutics - American Depositary Shares reported $9 million in Revenue and -$.05 earnings per share. This beat revenue expectation by $31,000 and exceeded earnings estimates by $.14.
The top ETF exchange traded funds that LKFT belongs to (by Net Assets): IBB, SBIO, AVDE, APIE, AVDS.
LKFT support price is $33.73 and resistance is $35.05 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LKFT shares will trade within this expected range on the day.